Eliminating copayments improves adherence, reduces adverse events in nonwhite patients

May 5, 2014

Research demonstrates that lowering copayments for cardiovascular medications results in better adherence and outcomes among all patients, but until now, little was known about whether lowering copayments could improve known disparities in cardiovascular care. New research finds that lowering copayments for medications following a heart attack could have a significant impact on reducing the racial and ethnic disparities that exist in cardiovascular disease.

These findings are published in the May issue of Health Affairs.

"African Americans and Hispanics with are up to 40 percent less likely than whites to receive secondary prevention therapies, such as aspirin and beta-blockers," said Niteesh Choudhry, MD, PhD, lead study author and associate physician in the Division of Pharmacoepidemiology at Brigham and Women's Hospital (BWH) and associate professor at Harvard Medical School. "Our research demonstrates that not only does eliminating medication copayments following a positively impact the disparity we know exists in and improve outcomes for nonwhite patients, it also has the potential to dramatically reduce healthcare spending for this high-risk group."

Researchers analyzed self-reported race and ethnicity data for participants in the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial, and found that rates of were significantly lower, and rates of adverse clinical outcomes - readmission for a major vascular event or coronary revascularization— were significantly higher, for nonwhite patients than for white patients.

Researchers report that providing full drug coverage (no copayment) increased medication adherence in both groups. Among nonwhite patients, it also reduced the rates of major vascular events or revascularization by 35 percent and reduced total by 70 percent. Interestingly, providing full coverage had no effect on clinical outcomes and costs for white patients.

"As part of our ongoing efforts to promote racial and ethnic equality, we wanted to further explore whether financial responsibility resulted in different health outcomes based on race or ethnicity. This important level of detail helps us design products and services that more effectively meet our members' health needs," said Wayne Rawlins, MD, national medical director for Racial and Ethnic Equality Initiatives at Aetna and co-author of the study.

The study and analysis of medication adherence and the impact on racial and is supported by an unrestricted research grant from Aetna to BWH and is part of ongoing collaborative work to understand the impact of health insurance on disparities in health care. Choudhry also receives research funding to study medication adherence from CVS/Caremark, who collaborated on the current study. Annual excess costs due to medication non-adherence in the U.S. have been estimated to be as much as $290 billion.

Related Stories

Value-based insurance plans can up Rx adherence

March 6, 2014

(HealthDay)—Value-based insurance design (VBID) plans with certain features aside from solely lowering cost sharing can increase medication adherence, according to a study published in the March issue of Health Affairs.

Recommended for you

New weapon in the fight against malnutrition

August 4, 2015

UBC scientists have opened the doors to new research into malnutrition by creating an animal model that replicates the imbalance of gut bacteria associated with the difficult-to-treat disease.

Can four fish oil pills a day keep the doctor away?

July 7, 2015

Fish oil is one of the most popular dietary supplements in the U.S. because of the perceived cardiovascular benefits of the omega-3 it contains. However, scientific findings on its effectiveness have been conflicting. New ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.